Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease

Inclusion Criteria for part A: - Established IBD diagnosis - Active disease: clinically active disease of the bowel is defined clinically as at least mild activity using dedicated scoring indices or biochemically active disease as defined by a fecal calprotectin \> 60 μg/g - Patients must be eligible for risankizumab therapy - Minimum age of 18 years - Written willing to sign a consent form - Clinical indication for an endoscopic procedure Inclusion Criteria for part B: - Established IBD diagnosis - Patients must be on risankizumab therapy for at least 14 weeks - Minimum age of 18 years - Written willing to sign a consent form - Clinical indication for an endoscopic procedure Exclusion Criteria for part A: - A female study patient who is pregnant or provides breastfeeding - A female study patient of premenopausal age who does not use any reliable form of contraception at the time of risankizumab-800CW administration and the following 10 weeks - Medical or psychiatric conditions that compromise the patient's ability to give willing to sign a consent form - Prior anti-IL23-specific therapy (IL23/IL12 combination therapy is not an exclusion criteria) - Active extra gastrointestinal manifestations of Crohn's disease (e.g. uveitis or pyoderma gangrenosum at vital locations) Exclusion Criteria for part B: - A female study patient who is pregnant or provides breastfeeding - A female study patient of premenopausal age who does not use any reliable form of contraception at the time of risankizumab-800CW administration and the following 10 weeks - Medical or psychiatric conditions that compromise the patient's ability to give willing to sign a consent form - Active extra gastrointestinal manifestations of Crohn's disease (e.g. uveitis or pyoderma gangrenosum at vital locations) Always talk to your doctor about whether this trial is right for you.